[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 5, Issue 2 (Int Biol Biomed J (In press) 2019) ::
IBBJ 2019, 5(2): 0-0 Back to browse issues page
Advancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects
Yousef Jafari Abarghan1, Arash Salmaninejad2, Atieh Eslahi2, Farzaneh Alizadeh1, Majid Mojarrad *3
1- Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2- Student Research Committee, Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3- Medical Genetics Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , majidmojarrad@gmail.com
Abstract:   (983 Views)
Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs receptors which are targeted against tumor-specific antigens, and enabled to arbitrarily T-cells function reprogramming. Approximately all of CAR-T cell based studies apply autologous CAR-T cells in which, modified T-cells are engineered using patient’s own T cells. Currently, four different generation of CAR-T cells have been developed, and the evolution of this kind of therapy illustrates an excellent example of the application of basic research into the clinical trial stage. However, development of allogenic CAR-T cells can be a turning point for CAR-T cells therapy. Appearance of the reliable gene editing approach, CRISPR/Cas9 system, provided a new hope for designing universal CAR-T cells which are off-the-shelf, and enable to use for treatment of any patient with any kind of tumor.This review outlined four different generations of CAR-T cells. Also, we discussed different types of genome editing systems especially CRISPR/Cas9 system, and their capabilities for generating engineered T-cells. Additionally, we tried to explain challenges faced in improving universally generated T-cells.  
Keywords: CAR-T cells, cancer, therapy, CRISPR/Cas9 system
     
Type of Study: Review | Subject: Cell Biology
Received: 2019/06/15 | Accepted: 2019/06/28 | Published: 2019/07/26
Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Jafari Abarghan Y, Salmaninejad A, Eslahi A, Alizadeh F, Mojarrad M. Advancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects. IBBJ. 2019; 5 (2)
URL: http://ibbj.org/article-1-227-en.html


Volume 5, Issue 2 (Int Biol Biomed J (In press) 2019) Back to browse issues page
International Biological and Biomedical Journal
Persian site map - English site map - Created in 0.05 seconds with 32 queries by YEKTAWEB 3949